CuII(atsm) improves motor function and extends survival in multiple mouse models of amyotrophic lateral sclerosis, including when administered post-symptom onset [180,181,182,183,184,185], and has recently been shown to activate Nrf2 in mice [79]. This evidence concerns the gene NFE2L2 and amyotrophic lateral sclerosis.